

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

2

Complete II Known				
Application Number	10/729,795			
Filing Date	December 5, 2003			
First Named Inventor	Walters			
Art Unit	1644			
Examiner Name	Zachary S. Skelding			
Attorney Docket Number	011823-012510US			

Examiner Initials* No.* Document Number Number Number Norther Norther Relevant Pagasages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Cite		Foreign Patent Document			Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
Initials* No.		Coantry Code ³	Number*	Gnd Code [®] (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	T*
	/							
	/_							
								ļ
	1							<u> </u>

Examiner	Date	1	
Signature	Considered		
0.80.0.0	 <u> </u>	<u> </u>	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ° For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 il possible. ³ Applicant is to place a check mark here if English language Translation is attached. 60990792

Substitute for form 1449B/PTO				Complete If Known			
INFORMATION DISCLOSURE				Application Number	10/729,795		
				Filing Date	December 5, 2003		
STATEMENT BY APPLICANT				First Named Inventor	Walters		
				Art Unit	1644		
(Use as many sheets as necessary)				Examiner Name	Zachary S. Skelding		
Sheet	2	of	2	Attorney Docket Number	011823-012510US		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
/ZS/	AA	CARPENTER et al., "A humanized non-FcR-binding antiCD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease," <u>Blood</u> , 99(8):2712-2719 (2002).		
/ZS/	ΑВ	HEAD et al., "Inflamatory Bowel Disease Part I: Ulcerative Colitis Pathophysiology and Conventional and Alternative Treatment Options," <u>Alternative Medicine Review</u> , 8(3):247-283 (2003).		
/ZS/	AC	TUVLIN et al., "Novel therapies in the treatment of ulcerative colitis," Expert Opin. Investig. Drugs, 12(3):483-490 (2003).		
	······································			
•••••••••••				

			····		
	Examiner	/Zachary Skelding/	Date Considered	07/04/2007	
Signature	,	00/10/00/00			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.